Resonance Health Ltd (ASX: RHT) Share Price and News

Dr Fuller is pharmaceutical physician and pharmacist with 30 years of experience across drug development, clinical research, regulatory strategy and commercialisation. He is currently Chief Medical Officer of Dimerix Limited. He held senior roles at Genzyme and Orphan Medical.

Mr Harrison is a CEO and Non-Executive Director of public listed and private companies across a range of industries, including radiology and medical AI. He founded and was Managing Director of Capitol Health Ltd (ASX: CAJ) one of Australias radiology companies, and he is in capital markets, technology commercialisation, local and international M&A, and strategic restructuring and turnaround. He has international experience including in US, European, and Chinese markets.

Mr Wells is an experienced senior executive with commercial and legal experience in Australia, the United States of America and the United Kingdom. He has served as a Director and worked as a senior executive of public and private companies including ASX and US Nasdaq listed public companies. He has served as Chair of two non-profit organisations and has previously served as the Company Secretary of two ASX listed public companies and as the corporate secretary of a US Nasdaq listed public company.

Mr Panton has been a supporter of the Company and its technologies over a number of years and is a shareholder of Resonance Health. Mr Panton brings skills in business and marketing having run his own business. He is member of the Risk Committe.

Mr. Sistenich is Chief Executive Officer and a Director of Enlitic, Inc. (Enlitic), having previously served as its Non-Executive Chairman. He has 25 years of experience across healthcare, artificial intelligence, life sciences and institutional investing. He previously served as Chief Executive Officer and Non-Executive Director of Nohla Therapeutics. He has served as a Non-Executive Director of Opthea Limited. He is a Founding Partner of Aurenda Partners.

Dr Baroni has experience across industrial research, commercialisation of technology, asset valuations and investment banking services. He has managed innovation development and technology strategy in a company setting as well as being an investor in early stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research and valuations to clients. He is chair of Risk Committee.

Mr Brinkworth had a 22-year career with Gilead Sciences, Inc. (Nasdaq: GILD) (Gilead) during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD $27 billion. He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director - Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets. He led Gilead's commercial and access operations in the Asia Pacific (APAC) where he managed a geographically dispersed team and partners across 31 APAC countries. He also serves on a NFP Board for The Royal Lifesaving Society of Western Australia and is a NED on the boards of Lixa Pty Ltd, a biotech company focused on antimicrobial resistance.

-